Lobbying Information
Subject Matters
- Budget
- Economic Development
- Government Procurement
- Health
- Intellectual Property
- Research and Development
Subject Matter Details
Grant, Contribution or Other Financial Benefit, Policies or Program
- Engagement with the Government regarding the Strategic Innovation Fund
- FedDev Ontario Advanced Manufacturing Fund - advancing manufacturing of innovative pharmaceutical products in southern Ontario
Legislative Proposal, Bill or Resolution
- Food and Drugs Act and the bill formerly known as Bill C-51: An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts. Specifically, with respect to the renewal of the drug approval process.
Advocacy to ensure that Canada's review and approval process is timely, safe, effective, competitive and consistent with other jurisdictions.
Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
- Canada-European Union Comprehensive Economic Trade Agreement with respect to strengthening Intellectual Property Protection provisions under the Patent Act and related regulations.
- Legislation, regulations, policies and programs concerning the federal government's response to COVID-19, including pandemic preparedness, pharmaceutical and vaccine supply-chain management, and general administration of justice.
Legislative Proposal, Bill or Resolution, Regulation
- Canada-Europe Comprehensive Economic and Trade Agreement - Intellectual Property Provisions
Policies or Program
- Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.
- Canada’s Access to Medicines Regime (CAMR), certified under the Patent Act, which allows developing countries to access drugs at a lower cost, with regard to ensuring that Intellectual Property rights and anti-diversion mechanisms continue to be respected.
- Engage the Government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians.
- Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy
- National Immunization Strategy.
Advocacy to seek continued investment in vaccines funding and an overall strategy for prevention of disease in Canada.
- Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB are consistent with the mandate assigned by Parliament.
- Public Services and Procurement Canada (PSPC) Integrity Framework - Clarifying the process for procurement of vaccines and possibly pharmaceuticals under the evolving procurement framework.
- Science and Technology (S&T) Strategy: Mobilizing Science and Technology to Canada's Advantage.
Advocacy for measures which will allow for commercialization in health care to occur and for Canada to remain competitive internationally on Intellectual Property and other fronts.
- The Common Drug Review (CDR) process for reviewing new drugs and providing listing recommendations to publicly funded drug benefit plans in Canada.
Ensuring the access needs of Canadian patients are met by advocating on activities undertaken in the context of the CDR.
- The National Pharmaceutical Strategy (NPS) as agreed by First Ministers in 2004.
Advocacy for ways to increase access to medicines and vaccines for Canadian patients.
Policies or Program, Regulation
- Drug Re-importation - Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level re-importation legislation.
Regulation
- Patented Medicines (Notice of Compliance) Regulations which seek to balance the protection of Intellectual Property (IP) and patents with cost containment.
Advocacy to ensure that IP rights are respected and internationally competitive in order to promote Research and Development.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Canadian Heritage (PCH)
-
Correctional Service of Canada (CSC)
-
Employment and Social Development Canada (ESDC)
-
Finance Canada (FIN)
-
Health Canada (HC)
-
House of Commons
-
Indigenous Services Canada (ISC)
-
Innovation, Science and Economic Development Canada (ISED)
-
Justice Canada (JC)
-
Pacific Economic Development Canada (PacifiCan)
-
Patented Medicine Prices Review Board (PMPRB)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Public Services and Procurement Canada (PSPC)
-
Senate of Canada
-
Veterans Affairs Canada (VAC)
In-house Corporation Details
Description of activities
GLAXOSMITHKLINE IS ONE OF CANADA'S LARGEST RESEARCH-BASED PHARMACEUTICAL COMPANIES. GLAXOSMITHKLILNE OPERATES FOUR MAIN FACILITIES IN CANADA, INCLUDING ITS HEAD OFFICE AND MANUFACTURING OPERATIONS IN MISSISSAUGA, AND ITS BUREAU D'AFFAURES DU QUEBEC IN MONTREAL. IN TOTAL GLAXOSMITHKLINE EMPLOYS APPROXIMATELY 1,800 PEOPLE ACROSS THE COUNTRY. GSK IS A LEADER IN MANY IMPORTANT THERAPEUTIC AREAS, INCLUDING RESPIRATORY, CENTRAL NERVOUS SYSTEM, ANTI-INFECTIVES AND GASTRO INTESTINAL/METABOLIC. GLAXOSMITHKLINE INVESTS MORE THAN $100 MILLION IN RESEARCH & DEVELOPMENT IN CANADA EACH YEAR. GLAXOSMITHKLINE'S $120 MILLION MANUFACTURING OPERATIONS PRODUCE MORE THAN 100 MEDICINES AND 20 MILLION UNITS ANNUALLY.
Responsible officer name and position during the period of this registration
Sridhar Venkatesh,
General Manager and President
Government funding
End date of the last completed financial year:
2022-12-31
List of Government Funding
Government Institution
|
Funding Received in Last Financial Year
|
Funding Expected in Current Financial Year
|
Innovation, Science and Economic Development Canada (ISED)
|
$0.00
|
Yes
|
In-house Corporation Contact Information
Address:
100 Milverton Drive, Suite 800
Mississauga, ON L5R 4H1
Canada
Telephone number:
905-819-3000
Parent Company Information
- GlaxoSmithKline plc
-
980 Great West Road
Brentford, Middlesex TW89GS
United Kingdom
Subsidiary Beneficiary Information
- GlaxoSmithKline Biologicals / GlaxoSmithKline Biologiques
-
525 Cartier Blvd. W.
Laval, QC H7V 3S8
Canada
- ID Biomedical Corporation of Quebec / Corporation ID Biomedical du Quebec
-
2323 Du Parc-Technologique Boul.
Quebec, QC G1P 4R8
Canada
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Ranya El-Masri,
VP Public Affairs and Reimbursement |
No public offices held
- Josee Gravelle,
General Counsel |
No public offices held
- Emma Walmsley,
Global Chief Executive Officer |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Emily Beduz,
Manager, Federal Affairs |
No public offices held
- Stephen Burke,
National Policy Manager - Oncology |
No public offices held
- Daniel Clow,
Director, Ethics and Compliance |
No public offices held
- Alain Couture,
External Affairs Manager |
No public offices held
- Ryan Lock,
Manager, National Policy - Federal Affairs |
No public offices held
- Kevin Sauve,
National Public Health Manager |
No public offices held
- Shawn White,
External Affairs Manager |
No public offices held